Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Tech Coloproctol ; 18(6): 529-33, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24197902

ABSTRACT

BACKGROUND: The aim of the present study was to determine the efficacy of mesenteric embolization in the management of acute haemorrhage from the colon. METHODS: A retrospective review was performed of a consecutive series of patients who underwent selective arterial embolization between 2002 and 2010 at two Australian institutions. An analysis was performed of each patient's present and past medical history, procedural details and subsequent post-procedural recovery. RESULTS: Seventy-one patients were reviewed in the study. Sixty-one patients (86 %) had immediate cessation of bleeding following embolization. In total, 20 % had some form of morbidity due to mesenteric embolization being performed, the three most common being worsening renal function, groin haematoma and contrast allergy (11, 9 and 7 %, respectively). Only one patient developed superficial bowel ischaemia. Overall, 11 patients (18 %) had recurrent bleeding. Of these patients, five had repeat embolization. Of the patients who underwent re-embolization, three stopped bleeding. Surgery was required in 5 patients 2 of whom died postoperatively of systemic complications. CONCLUSIONS: Colonic bleeding can be treated successfully in most patients by embolization, without causing ischaemia. Eighteen per cent of patients rebleed during the first hospital admission, and 20 % patients experienced a procedure-related complication. In those patients that proceed to surgery, the morbidity, mortality and length of hospital stay increase dramatically.


Subject(s)
Colon/blood supply , Colonic Diseases/therapy , Embolization, Therapeutic/methods , Gastrointestinal Hemorrhage/therapy , Adult , Aged , Aged, 80 and over , Colonic Diseases/etiology , Female , Gastrointestinal Hemorrhage/etiology , Humans , Male , Middle Aged , New South Wales , Recurrence , Retreatment , Risk Factors , Survival Rate , Treatment Outcome , Western Australia
2.
Pathology ; 44(7): 587-95, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23111474

ABSTRACT

Testing for HER2 positivity in breast cancer carries implications for prognosis and therapeutic response in patients. In recent times there have been numerous developments and refinements in the available technologies for HER2 testing. In addition to this, guidelines have been developed and modified in an attempt to improve reliability and accuracy of testing. Immunohistochemistry and FISH testing have been the most widely used methodology, and the technique which has the largest knowledge base. Some of the inherent disadvantages have prompted the development of newer brightfield techniques which overcome some of these issues. There is gathering experience with these emerging technologies. Despite efforts to optimise and standardise procedures there remains a small percentage of cases that continue to be unresolved, whether this be due to issues of polysomy of chromosome 17, other complex genetic changes or analytical/interpretative issues. An ideal method for the resolution of these equivocal results should be considered in a specialised testing/referral centre, and this may include karyotyping studies of chromosome 17 or multiple probes for chromosome 17 using fluorescence in situ hybridisation or multiplex ligation-dependent probe amplification.It is timely to review of some of the newer techniques available for routine testing and approaches for cases which prove difficult to resolve using conventional testing methodology.


Subject(s)
Biomarkers, Tumor/genetics , Breast Neoplasms/diagnosis , Chromosomes, Human, Pair 17/genetics , Receptor, ErbB-2/genetics , Biomarkers, Tumor/metabolism , Breast Neoplasms/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry/methods , In Situ Hybridization/methods , Karyotyping/methods , Multiplex Polymerase Chain Reaction/methods , Prognosis , Receptor, ErbB-2/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...